Aminolevulinic acid - Shanghai Fudan-Zhangjiang Bio-Pharmaceutical
Alternative Names: 5-aminolevulinic acid; ALA; ALA PDT; Aminolevulinic acid hydrochlorideLatest Information Update: 08 Aug 2024
At a glance
- Originator Shanghai Fudan-Zhangjiang Bio-Pharmaceutical
- Class Amino acids; Antianaemics; Antineoplastics; Diagnostic agents; Imaging agents; Keto acids; Levulinic acids; Nootropics; Skin disorder therapies; Small molecules; Vascular disorder therapies
- Mechanism of Action Photosensitisers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Condylomata acuminata
- Phase III Glioma
- Phase II Cervical intraepithelial neoplasia; Human papillomavirus infections
- Phase I/II Acne vulgaris
- No development reported Basal cell cancer
Most Recent Events
- 19 Jun 2024 Phase-III clinical trials in Glioma in China (PO) (NCT06417281)
- 17 May 2024 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical plans to initiates a phase III trial for Glioma (Diagnostic, Newley-diagnostic, Metastatic disease) in China (PO) (NCT06417281)
- 06 Mar 2024 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical completes a phase II trial in Cervical intraepithelial neoplasia and Human papillomavirus infections in China (Topical) (NCT06439433)